期刊
MAGNETIC RESONANCE IN MEDICINE
卷 81, 期 3, 页码 1935-1946出版社
WILEY
DOI: 10.1002/mrm.27494
关键词
AAZTA; fibrin-fibronectin complex; prostate cancer; T-1-weighted MRI; targeting peptide
资金
- AIRC Investigator Grant [IG-14565]
Purpose: Prostate cancer (PCa) is the most widespread tumor affecting males in Western countries. We propose a novel MRI molecular tetrameric probe based on the heptadentate gadolinium (Gd)-AAZTA (6-amino-6-methylperhydro-1,4-diazepine-tetraacetic acid) that is able to in vivo detect PCa through the recognition of the fibrin-fibronectin (FB-FN) complex. Methods: The peptide CREKA (Cys-Arg-Glu-Lys-Ala), targeting the FB-FN complex in the reactive stroma of the tumor, was synthesized by solid phase peptide synthesis (SPPS) and conjugated to the tetramer dL-(Gd-AAZTA)(4). The resulting probe was characterized by H-1 relaxometry, tested in vitro on FB clots and in vivo on an orthotopic mouse model of PCa. Results: CREKA-dL-(Gd-AAZTA)(4) showed a remarkable relaxivity of 18.2 mM(Gd)(-1s-1) (0.47 T, 25 degrees C) because of the presence of 2 water molecules (q = 2) in the inner coordination sphere of each Gd3+ ion, whose rotational motion (tau(R)) is lengthened as the result of the relatively high molecular weight. The probe displayed a detectable affinity for plasma-derived FB clots. On intravenous injection of the probe in an orthotopic mouse model of PCa, a significant increase in the prostate T-1 contrast (similar to 40%) was observed. The MRI signal appears statistically higher either with respect to the one observed for the control probes and to the one detected when CREKA-dL-(Gd-AAZTA)(4) was administered to healthy animals. Conclusions: This study demonstrated the ability of the CREKA-dL-(Gd-AAZTA)(4) probe to specifically localize in prostate tumor after injection. The high relaxivity of the probe allows the reduction of the injected dose to 20 mu mol(Gd)/kg, yielding a good in vivo contrast enhancement in the region of prostate tumor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据